Lisata Therapeutics and Valo Therapeutics partner in preclinical study on cancer immunotherapy
Portfolio Pulse from
Lisata Therapeutics Inc and Valo Therapeutics Oy have announced a preclinical research collaboration to explore a novel cancer treatment combination targeting melanoma. The study will investigate the potential benefits of combining Lisata's experimental drug, certepetide, with Valo's PeptiCRAd immunotherapy platform and a checkpoint inhibitor.
November 06, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lisata Therapeutics has partnered with Valo Therapeutics to conduct a preclinical study on a novel cancer treatment targeting melanoma. This collaboration could enhance Lisata's drug development pipeline and potentially lead to new treatment options.
The partnership with Valo Therapeutics to explore a novel cancer treatment could positively impact Lisata Therapeutics by enhancing its drug development pipeline. Successful preclinical results may lead to further clinical trials and potential market opportunities, which could boost investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90